PDSB

About PDSB

PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is developing a pipeline of targeted immunotherapies for cancer and infectious diseases based on its Versamune, Versamune plus PDS0301, and Infectimune T cell-activating platforms. Its lead clinical candidate, PDS0101, is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. PDS0101, has demonstrated the ability to reduce tumors and stabilize disease in combination with approved and investigational therapeutics in patients with a range of HPV16-associated cancers. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration and longevity of T cells in the tumor microenvironment. PDS0102, PDS0103, PDS0104, PDS0201, PDS0202, and PDS0203 are also in its pipeline of Versamune and Infectimune-based therapies.